Final Program and Schedule

EDUCATIONAL SESSIONS

10:00 a.m.-11:30 a.m.

• SESSION 1: NATURAL PRODUCT-DERIVED AGENTS
  Chairperson: Dennis C. Liotta, Emory University, Atlanta, GA

  
  Title to be announced
  Dennis C. Liotta

  Use of Natural Products as the Scaffolds for the Design of Molecularly Targeted Agents for Cancer Treatment and Prevention
  Shaomeng Wang, University of Michigan, Ann Arbor, MI

  Sphingolipid Biodiversity and Cancer: An Endless Source of Surprises in Cell Regulation and Novel Strategies for Cancer Chemoprevention and Chemotherapy
  Alfred H. Merrill, Georgia Institute of Technology, Atlanta, GA

• SESSION 2: ADVANCED METHODS AND TECHNOLOGIES FOR BIOMARKER RESEARCH
  Chairperson: John D. Groopman, Johns Hopkins University, Baltimore, MD

  
  Quantitative Mass Spectrometry for Small Molecules and Gene Mutations
  John D. Groopman

  A Genome-wide Association Study of Breast Cancer
  David J. Hunter, Harvard University, Boston, MA

  The Integration of New in vivo and in vitro Diagnostic Technologies with New Therapeutics to Accelerate Development and Approval of New Cancer Therapeutics
  James R. Heath, California Institute of Technology, Pasadena, CA

• SESSION 3: INFLAMMATION
  Chairperson: Tak W. Mak, Princess Margaret Hospital, Toronto, ON, Canada
  
  Title to be announced
  Tak W. Mak
  
  Macrophages Regulate Inflammation in the Tumor Microenvironment
  Jeffrey W. Pollard, Albert Einstein College of Medicine, Bronx, NY
  
  CXC Chemokines in Cancer
  Robert M. Strieter, University of Virginia School of Medicine, Charlottesville, VA

PROFESSIONAL ADVANCEMENT SESSION

CLICK HERE TO REGISTER

Panelists:

• Peter Greenwald, National Cancer Institute, MD
• Frank L. Meyskens, Jr., University of California at Irvine, Orange, CA
• William G. Nelson, V, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
• Brian J. Reid, Fred Hutchinson Cancer Research Center, Seattle, WA

EDUCATIONAL SESSIONS

1:00 p.m.-2:30 p.m.

• SESSION 4: MOLECULAR MECHANISMS OF AGING - RELATIONSHIP TO CANCER PREVENTION
  Chairperson: Jerry W. Shay, UT Southwestern Medical Center, Dallas, TX 

  
  Aging and Cancer: Are Telomeres and Telomerase the Connection?
  Jerry W. Shay

  The Role of Genes in Protecting Against Age-related Disease in Cancer
  Nir Barzilai, Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY

  Interleukins at the Crossroad of Inflammation, Senescence, and Cancer
  Daniel S. Peeper, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  
  Translating Research in Aging to Clinical and Policy Settings
  Jeanne Mandelblatt, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC

• SESSION 5: PRECLINICAL MODELS FOR AGENT DISCOVERY
  Chairperson: Haian Fu, Emory University School of Medicine, Atlanta, GA

  
  High-throughput Screen Technologies for New Agent Discovery at an Academic Setting
  Haian Fu

  Discovering New Drugs to Inhibit Prostate Cancer Metastasis
  Raymond C. Bergan, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  The Development of Tractable Mouse Models to Study Therapeutic Response
  Michael T. Hemann, Massachusetts Institute of Technology, Cambridge, MA

• SESSION 6: BIOSPECIMEN AVAILABILITY
  Chairperson: Ian M. Fore, National Cancer Institute, Rockville, MD
  
  PLCO Biospecimen Resource for Etiologic and Early Marker Research
  Claire Zhu, National Cancer Institute-DCP, Bethesda, MD
  
  The Role of Informatics in Biospecimen Availability
  Ian M. Fore
  
  Tissue Resources for Translational Research
  James W. Jacobson, National Cancer Institute, Rockville, MD

EDUCATIONAL SESSIONS

2:45 p.m.-4:15 p.m.

• SESSION 7: VITAMIN D - THE CANCER CONNECTION
  Chairperson: Michael F. Holick, Boston University School of Medicine, Boston, MA 

  
  Vitamin D and the Cancer Connection: A D-Lightful Story
  Michael F. Holick

  Ecological and Other Studies Supporting a Role of Vitamin D in Reducing the Risk of Cancer and Increasing Survival with Cancer
  William B. Grant, Sunlight, Nutrition, and Health Research Center, San Francisco, CA

  Role of Vitamin D in Prevention of Cancer: Dose-Response Relationships
  Cedric F. Garland, University of California at San Diego, La Jolla, CA

• SESSION 8: TECHNOLOGIES
  Chairperson: Frank L. Meyskens, Jr., University of California at Irvine, Orange, CA

  
  How Should We Optimize Technology to Allow Personalized Medicine?
  Frank L. Meyskens, Jr.

  Designing Life Chips and their Impact for the Prevention and Early Detection of Cancer
  Nancy L. Allbritton,  University of North Carolina, Chapel Hill, NC 

  Advanced Imaging Strategies for Prevention and Early Detection
  Orhan Nalcioglu, University of California at Irvine, Orange, CA

• SESSION 9: NEW DIMENSIONS OF EFFICACY AND SAFETY IN CLINICAL TRIALS FOR CANCER PREVENTION
  Chairperson: Jaye L. Viner, National Cancer Institute, Bethesda, MD
  
  Results of a Phase III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer
  Anita L. Sabichi, UT M.D. Anderson Cancer Center, Houston, TX
  
  Prevention of Non-Melanoma Skin Cancer with Celecoxib
  Craig A. Elmets, University of Alabama School of Medicine, Birmingham, AL
  
  Celecoxib Trials and Clinical Quandaries
  Jaye L. Viner

SPECIAL SESSION: NCI OPPORTUNITIES FOR JUNIOR INVESTIGATORS

Chairperson: Jonathan S. Wiest, Center for Cancer Training, National Cancer Institute, Bethesda, MD
4:30 p.m.-5:30 p.m.

Panelists:

• Jessica M. Faupel-Badger, Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD
• Lester S. Gorelic, Cancer Training Branch, National Cancer Institute, Rockville, MD
• Jackie A. Lavigne, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
• Jonathan S. Wiest

OPENING PLENARY SESSION

6:00 p.m.-7:30 p.m.

DISTINGUISHED LECTURE ON TARGETS FOR CANCER PREVENTION
Prevention of Cervical Cancer in Current and Future Generations by HPV Vaccination and Other Approaches
Douglas R. Lowy, National Cancer Institute, Bethesda, MD

KEYNOTE ADDRESS
Cancer and Aging: Rival Demons?
Judith Campisi, Lawrence Berkeley National Laboratory, Berkeley, CA

OPENING RECEPTION

7:30 p.m.-9:00 p.m.

PLENARY SESSION 1: MOLECULAR TARGETS IN CANCER PREVENTION

Chairperson: Phillip A. Dennis, National Cancer Institute, Bethesda, MD
7:45 a.m.-9:45 a.m.

Genetic Opportunities for Colon Cancer Prevention
Sanford D. Markowitz, Case Western Reserve University, Cleveland, OH

Studies on Tumor- and Metastasis-initiating Cells in the Lung: Novel Targets for Lung Cancer Prevention?
Jonathan M. Kurie, UT M.D. Anderson Cancer Center, Houston, TX

Progress in the Targeted Prevention of Lung Cancer
Fadlo R. Khuri, Emory University Winship Cancer Institute, Atlanta, GA

The Role of Regulatory T Cells in K-Ras Driven Lung Cancer
Phillip A. Dennis

CONCURRENT SESSIONS

10:00 a.m.-11:45 a.m.

• SESSION 1: PROSTATE CANCER PREVENTION
  Chairperson: William G. Nelson, V, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  
  Genetic and Epigenetic Changes in Prostate Cancer as Targets for Prevention
  William G. Nelson, V
  
  The Prostate Cancer Prevention Trial: An Update on Pathology
  M. Scott Lucia, University of Colorado Denver School of Medicine, Aurora, CO
  
  Prostate Cancer Risk Reduction Through Lifestyle: New Insights from the Prostate Cancer Prevention Trial
  Alan Kristal, Fred Hutchinson Cancer Research Center, Seattle, WA
  
  *A Randomized Factorial Trial of Vitamins E and C in the Prevention of Cancer in Men: The Physicians' Health Study II
  Howard Sesso, Brigham and Women's Hospital, Boston, MA

• SESSION 2: OVARIAN CANCER RISK REDUCTION
  Chairperson: Karen A. Johnson, National Cancer Institute, Bethesda, MA

  
  BRCA-associated Risk for Ovarian/Primary Peritoneal Carcinoma: The Role of Prophylactic Salpingo-oophorectomy
  Timothy R. Rebbeck, University of Pennsylvania Cancer Center, Philadelphia, PA
  
  Ovarian Cancer Risk Management Following Breast/Ovarian Cancer Gene Testing
  Marc D. Schwartz, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC

  Prospects for Targeted Reduction of Ovarian Cancer Risk
  Karen A. Johnson
  
  *Investigation of Mismatch Repair Deficiency in Ovarian Cancers
  Tuya Pal, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

• SESSION 3: HEMATOLOGIC MALIGNANCIES
  Chairperson: Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, MA

  
  Molecular Determinants and Progression Risk in MGUS
  Nikhil C. Munshi

  Immune Surveillance in MGUS: A Balance between Immune Effector and Regulatory T Cells?
  Qing Yi, UT M. D. Anderson Cancer Center, Houston, TX

  Therapeutic Interventions to Prevent Progression of MGUS to Multiple Myeloma
  Shaji Kumar, Mayo Clinic, Rochester, MN

SPECIAL SESSION: ACHIEVING THE POTENTIAL OF CHEMOPREVENTION RISK REDUCTION

Chairpersons: Ernest T. Hawk, UT M.D. Anderson Cancer Center, Houston, TX and Frank L. Meyskens, Jr., University of California at Irvine, Orange, CA
12:00 p.m.-1:00 p.m.

How Health Communications Turned Cardiovascular Prevention into a Reality
Lisa Sparks, Chapman University, Orange, CA

Incenting Investment in Risk Reduction
Gerard T. Kennealey, Oncology Drug Development, Wilmington, DE

Chemoprevention: Poised for Success
Peter Greenwald, National Cancer Institute, Bethesda, MD

CONCURRENT SESSIONS

1:00 p.m.-2:45 p.m.

• SESSION 4: EARLY PHASE CLINICAL TRIALS OF CANCER PREVENTIVE AGENTS
  Chairpersons: Eva Szabo, National Cancer Institute, Bethesda, MD, and H-H. Sherry Chow, University of Arizona, Tucson, AZ
  
  Phase II Study of Genistein in Bladder Cancer
  Edward Messing, University of Rochester, Rochester, NY
  
  Presurgical Trials in Chemoprevention Drug Development
  Howard H. Bailey, University of Wisconsin, Madison, WI
  
  

  Phase 1b Sulindac Study for Women at High Risk for Breast Cancer
  Patricia A. Thompson, University of Arizona, Tucson, AZ
  
  Phase II Trial of Bexarotene in Women at High Risk of Breast Cancer: Comparison of Protein and RNA Biomarkers
  Powel H. Brown, Baylor College of Medicine, Houston, TX
  
  Commentary on Study Designs for Early Phase Breast Cancer Prevention Trials
  H-H. Sherry Chow
  
  Randomized Phase II Trial of Budesonide in High-Risk Population with Undetermined Lung Nodules Detected at Screening Low Dose CT Scan
  Giulia Veronesi, European Institute of Oncology, Milan, Italy

  Commentary on Study Designs for Early Phase Lung Cancer Prevention Trials
  Eva Szabo
  
  
• SESSION 5: ER STRESS, AUTOPHAGY, PROTEIN HOMEOSTASIS, AND PROTEIN DEGRADATION
  Chairperson: Vassiliki Karantza-Wadsworth, The Cancer Institute of New Jersey, New Brunswick, NJ

  
  ER Stress, Protein Folding, and Oxidative Stress
  Randal J. Kaufman, Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI
  
  Autophagy and Mammary Tumorigenesis: Role of Metabolic and ER Stress Management
  Vassiliki Karantza-Wadsworth

  Modulating ER Stress-induced Autophagy to Cancer Control
  Xiao-Ming Yin, University of Pittsburgh, Pittsburgh, PA
  
  *A Novel Function of Poly(ADP-ribose) Polymerase-1 In Modulation of Autophagy and Necrosis Under Oxidative Stress
  Han-Ming Shen, National University of Singapore, Singapore

• SESSION 6: ENERGY BALANCE AND PHYSICAL ACTIVITY
  Chairperson: Lucile L. Adams-Campbell, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC

  Obesity, Physical Activity, and Colon Polyps: Black Women's Health Study
  Lucile L. Adams-Campbell

  Fitness versus Fatness in Breast Cancer Risk and Prognosis
  Anne McTiernan, Fred Hutchinson Cancer Research Center, Seattle, WA

  Pediatric Obesity Research: A Transdisciplinary Approach
  Donna Spruijt-Metz, University of Southern California, Los Angeles, CA

  *Physical Activity and Postmenopausal Breast Cancer: Effect Modifications by Hormone Receptor Status and Breast Cancer Risk Factors
  Karen Steindorf, German Cancer Research Center, Heidelberg, Germany
  
  *A Pooled Analysis of 14 Cohort Studies of Body Mass Index and Pancreatic Cancer Risk
  Jeanine M. Genkinger, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC

PLENARY SESSION 2: INTERNATIONAL CANCER PREVENTION STRATEGIES

Chairperson: Christopher P. Wild, University of Leeds, Leeds, United Kingdom
3:00 p.m.-5:00 p.m.

Global Trends in Cancer Incidence: Priorities for Prevention
Michael J. Thun, American Cancer Society, Atlanta, GA

Foodborne Toxins in Developing Countries
Christopher P. Wild 

Nutrition and Cancer - What Have We Learned So Far?
Elio Riboli, Imperial College, London, United Kingdom

Cancer Screening in Developing Countries
Rengaswamy Sankaranarayanan, International Agency for Research on Cancer, Lyon, France

AACR-PREVENT CANCER FOUNDATION AWARD LECTURE

5:00 p.m.-6:00 p.m.

Optimizing Chemoprevention by Minimizing Risk-Benefit and Maximizing Risk-Reduction
Frank L. Meyskens, Jr., University of California at Irvine, Orange, CA

BEHAVIORAL SCIENCE NETWORKING EVENT

6:00 p.m.–7:30 p.m.

Sponsored by the AACR Task Force on Behavioral Science and Cancer

POSTER SESSION A

6:00 p.m.-8:30 p.m.

PLENARY SESSION 3: TUMOR MICROENVIRONMENT / INFLAMMATION

Chairperson: Suzanne Ostrand-Rosenberg, University of Maryland Baltimore County, Baltimore, MD
7:45 a.m.-9:45 a.m.

Role of Stat3 in the Tumor Microenvironment
Hua Yu, City of Hope, Duarte, CA 

Inflammation-driven Myeloid-derived Suppressor Cells: Co-opting Anti-Tumor Immunity to Promote Tumor Progression
Suzanne Ostrand-Rosenberg   

Changing Chronic Inflammation from Foe to Friend
Augusto C. Ochoa, Louisiana State University Medical Center, New Orleans, LA

CONCURRENT SESSIONS

10:00 a.m.-11:45 a.m.

• SESSION 7: PERSONALIZED ASSESSMENT OF CANCER RISK
  Chairperson: Xifeng Wu, UT M.D. Anderson Cancer Center, Houston, TX

  
  Personalized Prediction of Bladder Cancer Risk: An Integrative Approach
  Xifeng Wu

  Discriminatory Accuracy from Single Nucleotide Polymorphisms in Models of Absolute Breast Cancer Risk
  Mitchell H. Gail, National Institutes of Health, Bethesda, MD
  
  Risk Prediction Model for Lung Cancer
  Margaret R. Spitz, UT M.D. Anderson Cancer Center, Houston, TX
  
  *Variation in VDR Pathway Genes and Renal Cancer Risk
  Sara Karami, National Cancer Institute, Rockville, MD

• SESSION 8: EPIGENETICS AND GENOME-WIDE SCREENING
  Chairperson: Brian J. Reid, Fred Hutchinson Cancer Research Institute, Seattle, WA

  
  Genome-wide Association Studies
  Stephen J. Chanock, National Cancer Institute, Bethesda, MD

  Genomic and Epigenomic Progression in Barrett's Esophagus
  Brian J. Reid

  DNA Methylation in Cancer: Implications for Screening and Prevention
  Jean-Pierre Issa, UT M. D. Anderson Cancer Center, Houston, TX
  
  *A European Genome-wide Association Study of Urinary Bladder Cancer
  Lambertus Kiemeney, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

• SESSION 9: INFECTION AND CANCER: BURDEN, DISCOVERY, AND CONTROVERSY
  Chairperson: Maura L. Gillison, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
  
  Infections and Cancer: The Global Burden
  Maura L. Gillison
  
  Cancer and Infection: Lessons from Immune Deficient Populations
  Andrew Grulich, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
  
  Current Controversies in the Viral Etiology of Cancer
  Eric A. Engels, National Cancer Institute, Rockville, MD
  
  Molecular Methods for Discovering Human Tumor Viruses: Merkel Cell Polyomavirus
  Huichen Feng, University of Pittsburgh Cancer Institute, Pittsburgh, PA
  
  *Trichomonas Vaginalis Infection and Prostate Cancer Incidence and Mortality: A Prospective Study in the Physicians' Health Study
  Jennifer R. Stark, Harvard School of Public Health, Boston, MA

CONCURRENT SESSIONS

1:00 p.m.-2:45 p.m.

• SESSION 10: PANCREATIC CANCER PREVENTION
  Chairperson: David A. Tuveson, CRUK Cambridge Research Institute, Cambridge, United Kingdom 

  
  Risk Stratification in Pancreatic Cancer: New Insights
  Gloria M. Petersen, Mayo Clinic, Rochester, MN
  
  Anatomic Detection and Early Surgery to Prevent Pancreatic Cancer in High Risk Kindreds
  Michael G. Goggins, Johns Hopkins University, Baltimore, MD
  
  Mouse Models to Prevent and Treat Pancreatic Cancer
  David A. Tuveson
  
  *Results of Surveillance for Hereditary Pancreatic Cancer Using MRI(CP)
  Hans Vasen, Leiden University Medical Centre, Leiden, The Netherlands

• SESSION 11: MECHANISMS OF CANCER HEALTH DISPARITIES
  Chairperson: Deborah J. Bowen, Boston University, Boston, MA

  
  Disparities in Mental Health Outcomes between Rural and Nonrural Cancer Survivors
  Michael A. Andrykowski, University of Kentucky, Lexington, KY
  
  Cultural Considerations In Outcomes Among Prostate Cancer Patients
  Chanita Hughes Halbert, University of Pennsylvania, Philadelphia, PA
  
  Does Access to Care Explain Disparities in Colon Cancer Mortality between Black and White Patients?
  Deborah J. Bowen
  
  *Poverty, Insurance Status, and Colorectal Cancer in Colorado: 1995-2006
  Alma Palisoc, University of Colorado, Denver, CO

• SESSION 12: EVOLUTION IN NEOPLASTIC PROGRESSION AND EPITHELIAL-MESENCHYNAL TRANSITION
  Chairperson: Carlo C. Maley, The Wistar Institute, Philadelphia, PA
  
  Clonal Evolution Over Time in Barrett's Esophagus
  Carlo C. Maley
  
  Evolution in Carcinogenesis
  Darryl K. Shibata, University of Southern California, Los Angeles, CA
  
  Epithelial-Mesenchynal Transition in Human Breast Cancer Progression: Cancer Stem Cell Attributes, Dissemination, and Dormancy
  Erik W. Thompson, University of Melbourne, Fitzroy, Australia
  
  *Snail-induced and EMT-mediated Early Lung Cancer Development: Promotion of Invasion and Expansion of Stem Cell Population
  Tonya Walser, University of Texas Southwestern Medical Center, Dallas, TX

PLENARY SESSION 4: COMMUNICATION CENTERS / CANCER PREVENTION

Chairperson: Robert P. Hawkins, University of Wisconsin, Madison, WI and Bradford W. Hesse, National Cancer Institute, Bethesda, MD
3:00 p.m.-5:00 p.m.

Introduction
Bradford W. Hesse 

Putting Cancer Communication Science to Work in Eliminating Cancer Disparities
Matthew Kreuter, St. Louis University, St. Louis, MO

How Do People Use Communication Media to Make Decisions about Cancer?
Robert C. Hornik, University of Pennsylvania, Philadelphia, PA

What it Takes to Sustain Consumer Health Informatics
Robert P. Hawkins

POSTER SESSION B

5:00 p.m.-7:30 p.m.

PLENARY SESSION 5: INTEGRATIVE PREVENTION

Chairperson: Ernest T. Hawk, UT M.D. Anderson Cancer Center, Houston, TX
8:00 a.m.-10:00 a.m.

Mechanistic Targets for Preventing Obesity-related Cancers
Stephen D. Hursting, University of Texas, Austin, TX

Antioxidants and Nutritional Intervention in Aging and Age-associated Disease
Mohsen Meydani, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA

Influence of Mother Nature's Pharmacopeia on Everyday Health and Wellbeing
John M. Pezzuto, University of Hawaii, Hilo, HI

CONCURRENT SESSIONS

10:15 a.m.-12:00 p.m.

• SESSION 13: BREAST CANCER PREVENTION
  Chairperson: Thea D. Tlsty, UCSF School of Medicine, San Francisco, CA

  
  Molecular Markers that Predict Future Formation of Malignant Breast Cancer
  Thea D. Tlsty

  Breast Tissue Composition and Risk of Breast Cancer
  Norman F. Boyd, Ontario Cancer Institute, Toronto, ON, Canada
  
  Intraductal Route of Breast Cancer Prevention and Therapy: From Preclinical Studies to Phase I Trials
  Saraswati Sukumar, Johns Hopkins University, Baltimore, MD
  
  *Is the Screening-related Increase of Breast Cancer Mainly Caused by Lesions that would Undergo Spontaneous Regression If Left Untreated? 
  Per-Henrick Zahl, Norwegian Institute of Public Health, Oslo, Norway

• SESSION 14: LUNG CANCER PREVENTION
  Chairperson: Jenny T. Mao, David Geffen School of Medicine at UCLA, Los Angeles, CA

  
  A Genome-wide Association Study Identifies Variation in Nicotine Acctylcholine Receptors that Influence Risk for Lung Cancer and Smoking Behavior
  Christopher I. Amos, UT M.D. Anderson Cancer Center, Houston, TX

  Proteomics Strategies for Lung Cancer Diagnostics
  Pierre P. Massion, Vanderbilt University, Nashville, TN

  Lung Cancer Chemoprevention with Celecoxib
  Jenny T. Mao
  

• SESSION 15: COLORECTAL CANCER PREVENTION - INFLAMMATION, INFECTION, AND IMMUNITY
  Chairperson: Andrew T. Chan, Massachusetts General Hospital, Boston, MA

  
  Aspirin, COX-2, and Colorectal Cancer
  Andrew T. Chan

  Gut Microbiota and Colorectal Adenoma
  Temitope Keku, University of North Carolina, Chapel Hill, NC

  Targeting APC-Deficient Cells for Apoptosis: A Therapeutic Approach for Colorectal Cancer Prevention
  Xiangwei Wu, UT M. D. Anderson Cancer Center, Houston, TX
  
  *Inhibition of Chronic Colitis-induced Carcinogenesis in IL-10 Knockout Mice by Dietary Supplementation of Black Raspberries
  Guang-Yu Yang, Northwestern University, Chicago, IL
  
  *Regression of Rectal Polyps in Familial Adenomatous Polyposis Patients with Freeze-dried Black Raspberries
  Gary D. Stoner, Ohio State University, Columbus, OH

DEPARTURE